Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449286) titled 'IFN-a in Relapse Prevention' on Feb. 27.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking University People's Hospital

Condition: Acute Myeloid Leukemia Myelodysplastic Syndromes

Intervention: Drug: IFN-a

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 1, 2026

Target Sample Size: 100

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07449286

Published by HT Digital Content Services with permission...